Each year, CLSA recognizes the achievements and honors excellence of California’s life sciences as it brings together industry leaders for an evening of celebration. Due to the COVID-19 pandemic, CLSA is pivoting the 2020 program to a digital campaign and virtual event. The campaign will begin on Monday, November 30th and run through Thursday, December...
A new product launch, a clinical study, or regulatory submission are all examples of projects in life sciences. In performing their jobs, PMs in the life sciences are taking on more cross-functional responsibilities. And while asked to wear many hats, they must still ensure the final product or program is delivered on time, within budget,...
The premier event in malignant and non-malignant hematology will be all-virtual Attend the world’s most comprehensive hematology event of the year for an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates on the most critical topics in hematology. Program Abstracts Registration Presenter Resources Exhibits Meeting Resources ASH-a-Palooza Past &...
The International Conference on Microbiome Engineering (ICME 2020) will bring together leaders and experts from cutting edge fields of microbiome engineering to discuss progress and needs to develop research, technology, and innovation.... Microbiomes consist of diverse microoganisms and viruses that exist in every environment Earth ranging from the deep ocean to human skin. Microbiomes are...
Speakers: Mark Merchant (Genentech), Maryland Franklin (Covance Preclinical Oncology), Karen Rex (Amgen), Willem Overwijk (Nektar Therapeutics), Shelley Ackerman (Bolt Biotherapeutics) Organizers: Gregory Wagner and Betty Chang Date: 2020-12-08 Time: 8:45-13:00 Pacific Time Registration fee: (USD): Location: Online via Zoom Major Sponsor: Vendor show vendors registered to date: Registration: http://www.PBSS.org Registration deadline:2020-12-07 (it will close sooner if the seating cap is reached) About the...
Extractable compounds with unknown identities are a common problem when conducting a chemical characterization study in support of medical device biocompatibility. With increasing instrument sensitivity, regulatory scrutiny, and the widespread adoption of the Analytical Evaluation Threshold (AET), unknown compounds are being seen in increasing number in many studies. Many manufacturers struggle to address and mitigate...
Day 1: December 08, 2020 - In Vivo Models and Case Studies with Targeted Therapeutics Symposium Overview and Relevance to Contemporary Issues in Development of Therapeutic Agents for Oncology (Mark Merchant, Genentech) Preclinical Mouse Models for Oncology and Immuno-oncology Applications (Maryland Franklin, Covance-Preclinical Oncology) Preclinical Development of AMG 510, a First-in-human Covalent Inhibitor of KRASG12C...
Massachusetts has long been the epicenter of biopharma research and development. Years of investment and collaboration between industry, education, and government has provided biopharma manufacturers a rich and deep talent landscape in Massachusetts. Join leaders in the biopharma industry and higher education as they discuss current talent development assets, share initiatives to grow talent even...
Case Study: The project was started with the aim to identify lead series and lead compounds for the inhibition of NNMT to treat metabolic disorders. The project team faced numerous challenges such as a moderate ADME profile of the starting compounds, establishing biochemical assays for the target and several selectivity assays, establishing target engagement and...
Research shows that an effective investor relations program can account for a 30% variance in a company’s valuation. Investor communications is a vital function at any publicly traded company, and an active agenda topic at board meetings. We’ve assembled CFO’s and board members to share their perspective on key investor relations topics that matter to...
Attend the 3rd Annual Diversity, Equity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry. This virtual event will be held Tuesday, December 8 and will bring together leaders and decision makers in our industry for a solution-focused discussion on how to best drive action and create positive change. In addition to our keynote and Impact...
QB3 SEMINAR: MARTIN BABLER, FORMER CEO, PRINCIPIA BIOPHARMA. "BUILDING A BEST-IN-CLASS PLATFORM FOR IMMUNE-MEDIATED DISEASE" Sanofi recently acquired Principia Biopharma for $3.7 billion. Principia, founded in 2008, built a portfolio of drugs to treat immune-mediated conditions including multiple sclerosis, pemphigus and immune thrombocytopenia purpura, all currently in Phase 3 trials. The portfolio was developed using...
